Menu
Nick brings over 40 years of leadership in the life sciences tools and diagnostics industry, having shaped the strategic direction of companies like Agilent Technologies and Bio-Rad Laboratories. With two PhDs and deep expertise in chemistry, he served as President of Agilent’s Life Sciences Group, leading a $3 billion global business, including acquisitions such as Halo Genomics. At Bio-Rad, he was Life Science Group Operations Officer, driving market growth and innovation.
Nick is widely recognised for his strategic vision and operational excellence, with a passion for bringing new technologies to market and helping companies transition from start-up to scale-up. As an adviser to private equity firms like Summa Equity and Nordic Capital, he has guided investments in companies such as Olink, where he played a key role in its sale to Thermo Fisher for 34 billion SEK. His board experience spans several innovative companies, including 908 Devices, The Binding Site, and Velsera.
At Sciety, Nick leverages his extensive network and expertise to analyse potential investment opportunities and support the growth of portfolio companies, continuing to drive innovation and impact in the industry.